Keywords: phib/ii, combo, trial, topotarget/curagen, pxd101, opens, enrollment
PhIb/II combo trial of TopoTarget/Curagen's PXD101 opens for enrollment
Article | 27 March 2006
Danish drugmaker TopoTarget AS and USA-based CuraGen have initiated treatment in a new Phase Ib/II trial evaluating their histone ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
